North America Conjugate Vaccine Market (2018-2023)

North America Conjugate Vaccine Market (2018-2023)


  • Products Id :- NS416
  • |
  • Pages: 75-90
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

North America Conjugate Vaccine Market:

 

Conjugate vaccine is a type of vaccine that contains bacterial capsular polysaccharide, attached with a protein to enhance immunogenicity and protect against invasive diseases. North America is one of the most prominent markets for conjugate vaccines. The conjugate vaccine market in North America is expected to expand at a CAGR of 3.2%, leading to a revenue of USD 16.26 Bn by 2023. By volume, it is anticipated to reach 286.63 Million units by 2023 expanding at a CAGR of 3%.

 

Scheduled conjugated vaccinations, have eradicated health disparities and consequently led to lower rate of disease incidence.

 

Market Segmentation:

 

o Based on disease indication, the market is segmented into pneumococcal, haemophilus influenza type b, diphtheria-tetanus-pertussis, meningococcal and others. The highest penetration among paediatrics in North America was in the case of DTP vaccines.

o Based on end user, the market is segmented into pediatric and adult.

o Based on countries, the market is divided into U.S. and Canada.

 

Key growth factors:

 

North America is projected to be one of the most significant markets for conjugate vaccines during the forecast period, due to a rise in demand for pneumococcal, meningococcal vaccines, and other conjugate vaccines. Increased diagnosis and treatment are considered to fuel the North American conjugate vaccine market. Recommended vaccines and dosages are updated on a regular basis to comply with prevalent serogroups of infectious agents. For example, the CDC has its own immunization schedule for US citizens. This has increased the effectiveness of administered vaccines, which thereby increases the demand for the product, leading to increase in market sales.

 

Threats and key players:

 

o The North America conjugate vaccine market is expected to grow positively. But since it is a saturated market, the scope for significant growth is limited. In North America, the population above 65 years of age has decreased from 53,000,000 in 2014 to 51,900,000 in 2016. So, the demand for adult vaccines has also reduced. The overall penetration rate for the adult segment is lower than that of the pediatric segment.

o Major conjugate vaccine providers operating in the market are GlaxoSmithKline, Pfizer Inc., Merck, Novartis, Sanofi Pasteur, etc.

 

What's covered in the report?

 

1. Overview of the North America conjugate vaccine market

2. Market drivers and challenges in the North America conjugate vaccine market

3. Market trends in the North America conjugate vaccine market

4. Historical, current and forecasted market size data for North America based on disease indication (pneumococcal, haemophilus influenza type b, diphtheria-tetanus-pertussis, meningococcal conjugate vaccines)-by revenue and by volume

5. Historical, current and forecasted market size data for North America based on end user (pediatric and adult conjugate vaccines)-by revenue and by volume

6. Historical, current and forecasted market size data of conjugate vaccines by countries (U.S., Canada)-by revenue and by volume

7. Historical, current and forecasted market size data for country-wise segments-by revenue and by volume

8. Analysis of the competitive landscape and profiles of major companies operating in the North American market

 

Why buy?

 

o Understand the demand for conjugate vaccines to determine the viability of the market

o Understand the country-specific market size and observations for each segment

o Develop strategies based on the drivers, trends and highlights for each of the segments

o Evaluate the value chain to determine the workflow and to get an idea of the current position where you are placed

o Recognize the key competitors of this market and respond accordingly

o Identify the initiatives and growth strategies taken up by the major companies and decide on the direction for further growth

o Define the competitive positioning by comparing the products and services with the key players in the market

 

Customizations available

 

With the given market data, Netscribes offers customizations according to specific needs. Write to us at support@researchonglobalmarkets.com.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Chapter 1: Executive summary

1.1 Market scope and segmentation

1.2 Key questions answered in this study

1.3 Executive summary-I

1.4 Executive summary-II

 

Chapter 2: Market overview

2.1. Market definitions

2.2. North America market overview-by revenue

- North America historical (2015-2017) market revenue (USD Bn)

- North America forecasted (2018-2023) market revenue (USD Bn)

-Country-wise market (2018-2023) revenue (USD Bn)

2.3. North America market overview-by volume

- North America historical (2015-2017) market volume (Million units)

- North America forecasted (2018-2023) market volume (Million units)

- Country-wise (2018-2023) market volume (Million units)

2.4. North America market drivers and challenges

2.4.1. North America market drivers

2.4.2. North America market challenges

2.5. North America market trends

2.6. Value chain

2.7.1. Country-specific market overview-U.S.

- Observation

- Key competitors

2.7.1(A) Country-specific market overview-U.S. by revenue and by volume

- U.S. historical (2015-2017) market revenue (USD Bn)

- U.S. forecasted (2018-2023) market revenue (USD Bn)

- U.S. historical (2015-2017) market volume (Million units)

- U.S. forecasted (2018-2023) market volume (Million units)

2.7.2. Country-specific market overview-Canada

- Observation

- Key competitors

2.7.2(A) Country-specific market overview-Canada by revenue and by volume

- Canada historical (2015-2017) market revenue (USD Bn)

- Canada forecasted (2018-2023) market revenue (USD Bn)

- Canada historical (2015-2017) market volume (Million units)

- Canada forecasted (2018-2023) market volume (Million units)

 

Chapter 3: North America major segment overview-by disease indication

3.1. Disease indication: Pneumococcal, Hib-by revenue, by volume, CAGR

- Overview-by disease indication

- Market share (2015, 2018 & 2023): Pneumococcal-North America (USD Bn, Million units)

- Market share (2015, 2018 & 2023): Hib-North America (USD Bn, Million units)

3.2. Disease indication: DTP, Meningococcal-by revenue, by volume, CAGR

- Overview-by disease indication

- Market share (2015, 2018 & 2023): DTP-North America (USD Bn, Million units)

- Market share (2015, 2018 & 2023): Meningococcal-North America (USD Bn, Million units)

 

Chapter 4: North America major segment overview-by end user

4.1. End user: Pediatric, Adult-by revenue, by volume, CAGR

-Overview-by end user

- Market share (2015, 2018 & 2023): Paediatric-North America (USD Bn, Million units)

- Market share (2015, 2018 & 2023): Adult-North America (USD Bn, Million units)

 

Chapter 5: U.S.-by disease indication

5.1. U.S.: disease indication-Pneumococcal conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways

5.2. U.S.: disease indication-Haemophilus Influenza type b conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways

5.3. U.S.: disease indication-Diphtheria-Tetanus-Pertussis conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways

5.4. U.S.: disease indication-Meningococcal conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways

 

Chapter 6: U.S.-by end user

6.1. U.S.: end user-Pediatric & Adult conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Key takeaways

 

Chapter 7: Canada-by disease indication

7.1. Canada: disease indication-Pneumococcal conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways

7.2. Canada: disease indication-Haemophilus Influenza type b conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways

7.3. Canada: disease indication-Diphtheria-Tetanus-Pertussis conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways

7.4. Canada: disease indication-Meningococcal conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Highlights, Key takeaways

 

Chapter 8: Canada-by end user

8.1. Canada: end user-Pediatric & Adult conjugate vaccine market size (USD Bn, Million units) (2015, 2018, 2023), Key takeaways

 

Chapter 9: Competitive landscape

9.1. Company market share

- Top 5 companies

9.2. Company overview-GlaxoSmithKline

- Company snapshot

- Product offerings

- Growth strategies

- Initiatives

- Geographical presence

9.2(A) Executive profile-GlaxoSmithKline

9.3. Company overview-Pfizer Inc.

- Company snapshot

- Product offerings

- Growth strategies

- Initiatives

- Geographical presence

9.3(A) Executive profile-Pfizer Inc.

9.4. Company overview-Merck & Co.

- Company snapshot

- Product offerings

- Growth strategies

- Initiatives

- Geographical presence

9.4(A) Executive profile-Merck & Co.

9.5. Company overview-Novartis

- Company snapshot

- Product offerings

- Growth strategies

- Initiatives

- Geographical presence

9.5(A) Executive profile-Novartis

9.6. Company overview-Sanofi Pasteur

- Company snapshot

- Product offerings

- Growth strategies

- Initiatives

- Geographical presence

9.6(A) Executive profile-Sanofi Pasteur

9.7. Company overview-CSL Limited

- Company snapshot

- Product offerings

- Growth strategies

- Initiatives

- Geographical presence

9.7(A) Executive profile-CSL Limited

9.8. Company overview-Nuron Biotech Inc.

- Company snapshot

- Product offerings

- Growth strategies

- Initiatives

- Geographical presence

9.8(A) Executive profile-Nuron Biotech Inc.

 

Appendix

- List of tables

- Assumptions

- Conclusion

- Research methodology

- About Netscribes Inc.

 

Disclaimer: The Table of Contents (ToC) provided above contains the targeted coverage. The coverage is subject to change as we progress with the research

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

o GlaxoSmithKline

o Pfizer Inc.

o Merck & Co.

o Novartis

o Sanofi Pasteur

o CSL Limited

o Nuron Biotech Inc.

select a license
Single User License
USD 2499 INR 177904
Site License
USD 2499 INR 177904
Corporate User License
USD 2499 INR 177904

NEWSLETTER BY CATEGORY




Testimonials

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com